Conditions: Overweight Obesity
Keywords: PF-07081532
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 20
Healthy volunteers: yes

Brief summary:
The purpose of this study is to compare the amount of PF-07081532 in blood after taking two different forms of PF-07081532. This study is seeking participants who are at least 18 years of age and are overweight and/or obese. All study participants will receive a total of 2 single doses of this study medication in either form. Form A consists of a PF-07081532 20 mg immediate release tablet and a PF-07081532 60 mg immediate release tablet. Form B consists of a PF-07081532 80 mg immediate release tablet. Each single dose will be separated by a minimum of 6 days. The amount of PF-07081532 in the blood for 4 days after taking each single dose will be compared between the two different formulations of PF-07081532.

The total time that participants will take part in this study is about 70 days. The first visit is a screening visit to ensure that participants are appropriately qualified for the study. This will occur up to 28 days before the first single dose. Participants will be admitted into the clinic one day prior to the first single dose and will remain in the clinic for a total of 11 days. The study team will phone the participants 28 to 35 days after the last dose of study medication.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Formulation A (PF-07081532 20 mg plus 60 mg) intervention 2: Formulation B (PF-07081532 80 mg)
Intervention descriptions: intervention 1: Formulation A: administered as a 20 mg immediate release tablet and a 60 mg immediate release tablet intervention 2: Formulation B: administered as a 80 mg immediate release tablet

Protocol document:
Prot_000.pdf: 















































































































































































SAP_001.pdf: